Coopetition spectrum trading in cognitive radio networks

Spectrum trading is a promising method to improve spectrum usage efficiency. Several issues must be addressed, however, to enable spectrum trading that goes beyond conservative trading idle bands and achieve cooperation between primary and secondary users. In this paper, we argue that spectrum holes should be explicitly endogenous and negotiated by spectrum trading participants. To this end, we proposed an a Vickery auction based, coopetive framework to foster cooperation, while allowing competition for spectrum sharing. Incentive schemes and penalty for revocable spectrum are proposed to increase the spectrum access opportunities for SUs while protecting PUs spectrum value. A simultation study shows that the proposed framework outperforms conservative trading approaches, in a variety of scenarios with different levels of cooperation and bidding strategies. © 2013 IEEE

Coopetive spectrum trading - Creating endogenous spectrum holes

Dynamic spectrum access has been proposed to address the spectrum scarcity. Based on this access mode, secondary users are allowed to opportunistically operate when primary users are absent. Secondary Users are, however, required to relinquish the spectrum upon return of the incumbent spectrum holder. Although it improves spectrum utility, opportunistic spectrum access limits secondary users' access to exogenous spectrum holes vacated by primary users. We argue that spectrum holes should be endogenous, enabled by incentives to incumbent users to increase spectrum availability, while mitigating risk. To this end, we take a different perspective on dynamic spectrum sharing and propose a coopetive framework, whereby primary and secondary users engage in a cooperative, yet competitive, auction-driven spectrum sharing to enhance spectrum usage. In this framework, the primary users'spectrum is organized in three bands, namely exclusive usage, usage right and management right bands. Based on this structure, spectrum is traded as financial options to increase trading flexibility and capture the value primary and secondary users attach to spectrum access and usage. Spectrum trading between primary and secondary users is formalized as a utility maximization problem. Approximate solutions to this problem are derived and their performance is analyzed. The results show that spectrum trading, which combines revocable and exclusive leasing, provides higher utilities for both primary and secondary users. © 2014 Springer Science+Business Media New York

Coopetition spectrum trading - Creating endogenous spectrum holes

Dynamic spectrum access is an important way to alleviate the spectrum scarcity. Traditionally, secondary users are allowed to opportunistically operate when primary users are absent and buy idle bands from primary users. Although it improves the spectrum utility to some extents, it is not enough. In this paper, we argue that spectrum hole should be endogenous which means they should be negotiated by primary and secondary users. We proposed a novel spectrum sharing scheme with spectrum usage and management right. Further, we suggest spectrum trading as a financial option to capture the realistic usage and increase the trading flexibility. We show the superior of our model for primary users in deterministic and dynamic leasing environments. © 2013 ICST - The Institute for Computer Sciences, Social Informatics and Telecommunications Engineering

Shadow replication: An energy-aware, fault-tolerant computational model for green cloud computing

As the demand for cloud computing continues to increase, cloud service providers face the daunting challenge to meet the negotiated SLA agreement, in terms of reliability and timely performance, while achieving cost-effectiveness. This challenge is increasingly compounded by the increasing likelihood of failure in large-scale clouds and the rising impact of energy consumption and CO2 emission on the environment. This paper proposes Shadow Replication, a novel fault-tolerance model for cloud computing, which seamlessly addresses failure at scale, while minimizing energy consumption and reducing its impact on the environment. The basic tenet of the model is to associate a suite of shadow processes to execute concurrently with the main process, but initially at a much reduced execution speed, to overcome failures as they occur. Two computationally-feasible schemes are proposed to achieve Shadow Replication. A performance evaluation framework is developed to analyze these schemes and compare their performance to traditional replication-based fault tolerance methods, focusing on the inherent tradeoff between fault tolerance, the specified SLA and profit maximization. The results show that Shadow Replication leads to significant energy reduction, and is better suited for compute-intensive execution models, where up to 30% more profit increase can be achieved due to reduced energy consumption

Queueing algorithms with breakdowns in data bases modelling

summar

VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies

BACKGROUND: Transarterial chemoembolization (TACE) is the current standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC) and is also a treatment option for patients with liver metastases from colorectal cancer. However, TACE is not a curative treatment, and tumor progression occurs in more than half of the patients treated. Despite advances and technical refinements of TACE, including the introduction of drug-eluting beads-TACE, the clinical efficacy of TACE has not been optimized, and improved arterial therapies are required. OBJECTIVE: The primary objectives of the VEROnA study are to evaluate the safety and tolerability of vandetanib-eluting radiopaque embolic beads (BTG-002814) in patients with resectable liver malignancies and to determine concentrations of vandetanib and the N-desmethyl metabolite in plasma and resected liver following treatment with BTG-002814. METHODS: The VEROnA study is a first-in-human, open-label, single-arm, phase 0, window-of-opportunity study of BTG-002814 (containing 100 mg vandetanib) delivered transarterially, 7 to 21 days before surgery in patients with resectable liver malignancies. Eligible patients have a diagnosis of colorectal liver metastases, or HCC (Childs Pugh A), diagnosed histologically or radiologically, and are candidates for liver surgery. All patients are followed up for 28 days following surgery. Secondary objectives of this study are to evaluate the anatomical distribution of BTG-002814 on noncontrast-enhanced imaging, to evaluate histopathological features in the surgical specimen, and to assess changes in blood flow on dynamic contrast-enhanced magnetic resonance imaging following treatment with BTG-002814. Exploratory objectives of this study are to study blood biomarkers with the potential to identify patients likely to respond to treatment and to correlate the distribution of BTG-002814 on imaging with pathology by 3-dimensional modeling. RESULTS: Enrollment for the study was completed in February 2019. Results of a planned interim analysis were reviewed by a safety committee after the first 3 patients completed follow-up. The recommendation of the committee was to continue the study without any changes to the dose or trial design, as there were no significant unexpected toxicities related to BTG-002814. CONCLUSIONS: The VEROnA study is studying the feasibility of administering BTG-002814 to optimize the use of this novel technology as liver-directed therapy for patients with primary and secondary liver cancer. TRIAL REGISTRATION: ClinicalTrial.gov NCT03291379; https://clinicaltrials.gov/ct2/show/NCT03291379. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/13696

Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez)

<p>Abstract</p> <p>Introduction</p> <p>Triple-negative breast cancer (TNBC) is defined as a group of breast carcinomas that are negative for expression of hormone receptors (ER, PR) and Her2, we can distinguish between two groups: basal-like (ER-, PR-, Her2-, cytokeratin (CK) 5/6+ and/or Her1+) and unclassified subtype (ER-, PR-, Her2-, Her1- and CK5/6-).</p> <p>The aim of this study is to determine the clinicopathological, histological, therapeutic and prognostic features associated with this type of breast cancer.</p> <p>Methods</p> <p>This is a retrospective study of 366 female breast cancer patients, diagnosed between January 2007 and June 2010 at the Department of Pathology. Epidemiological, clinical, histological, therapeutic and evolutive data were analyzed. OS and DFS rates were estimated by Kaplan-Meier analysis and a log-rank test to estimate outcome.</p> <p>Results</p> <p>A total of 64 women were identified as having TNBC (17.5% of all female breast cancer patients), 12.6% were basal-like, 4.9% were unclassified subtype, with a median age of 45 years. The median histological tumor diameter was 4.3 cm. TNBC were most often associated with a high grade, 49.2% grade III (53% for unclassified subtype, 47.6% for basal-like). Vascular invasion was found in 26.6% of cases (22% for unclassified subtype and 28.3% for basal-like). For the lymph node involvement: 51% had positive lymph nodes, and 22.4% had distant metastases. Neoadjuvant chemotherapy was administered to 18% patients with 26% of complete pathologic response; therefore adjuvant chemotherapy was given to 82%. 98% received anthracycline based regimen and only 30% received taxanes.</p> <p>The Kaplan-Meier curves based showed the lowest survival probability at 3-years (49% of OS, and 39% of DFS).</p> <p>Conclusion</p> <p>TNBC is associated with young age, high grade tumors, advanced stage at diagnosis, difference chemo response compared to other subtypes, and shortest survival. Critical to optimal future management is accurate identification of truly triple negative disease, and adequately powered prospective TNBC trials to establish treatment efficacy and define predictive biomarkers.</p

Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma

<p>Abstract</p> <p>Background</p> <p>Hypoxia is associated with increased resistance to chemo- and radiation-therapy. Hyperoxic treatment (hyperbaric oxygen) has previously been shown to potentiate the effect of some forms of chemotherapy, and this has been ascribed to enhanced cytotoxicity or neovascularisation. The aim of this study was to elucidate whether hyperoxia also enhances any actual uptake of 5FU (5-fluorouracil) into the tumor tissue and if this can be explained by changes in the interstitium and extracellular matrix.</p> <p>Methods</p> <p>One group of tumor bearing rats was exposed to repeated hyperbaric oxygen (HBO) treatment (2 bar, pO₂= 2 bar, 4 exposures à 90 min), whereas one group was exposed to one single identical HBO treatment. Animals housed under normal atmosphere (1 bar, pO₂= 0.2 bar) served as controls. Three doses of 5FU were tested for dose response. Uptake of [³H]-5FU in the tumor was assessed, with special reference to factors that might have contributed, such as interstitial fluid pressure (P_if), collagen content, oxygen stress (measured as malondialdehyd levels), lymphatics and transcapillary transport in the tumors.</p> <p>Results</p> <p>The uptake of the cytostatic agent increases immediately after a single HBO treatment (more than 50%), but not 24 hours after the last repeated HBO treatment. Thus, the uptake is most likely related to the transient increase in oxygenation in the tumor tissue. Factors like tumor P_ifand collagen content, which decreased significantly in the tumor interstitium after repeated HBO treatment, was without effect on the drug uptake.</p> <p>Conclusion</p> <p>We showed that hyperoxia increases the uptake of [³H]-5FU in DMBA-induced mammary tumors <it>per se</it>, independently of changes in P_if, oxygen stress, collagen fibril density, or transendothelial transport alone. The mechanism by which such an uptake occur is still not elucidated, but it is clearly stimulated by elevated pO₂.</p